Securities Law

The company unveils a five-pillar ecosystem for its $SNACK token, targeting everything from Premier League payments to real estate and iGaming.

Oculis appoints former Cooley partner Katie Kazem as CLO, a strategic move to fortify governance ahead of pivotal data readouts for its late-stage eye drugs.

Mark Hunt, the architect of SIM's rise to an $86B powerhouse, has stepped down, leaving questions about the future of the firm he built from the ground up.

The biotech firm enacts a 1-for-25 stock split to avoid delisting, placing its promising cancer therapy pipeline under a brighter, more critical spotlight.

The Chinese education firm is back in the NYSE's good graces, but a 12-month review period means the real test of stability has just begun.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?

A new report reveals a looming crisis: rising healthcare costs will consume more than 100% of Social Security benefits for future generations of retirees.

VanEck's new VAVX offers investors the first regulated US vehicle for AVAX exposure, complete with staking rewards, signaling a new era for altcoins.

The ETF provider launched four new funds for traders to short APLD, IREN, LCID, and NBIS, amplifying both risk and potential reward in volatile sectors.

Data center firm EdgeMode alleges a "pay-to-play" scheme after a negative report, detailing its innovative energy strategy to bypass grid constraints for AI.

TradeStation's new protocol lets traders talk to their accounts via AI, heralding a new era of conversational finance, but not without significant risks.

A new report reveals a paradoxical trend: plaintiff firms are filing fewer securities lawsuits but securing record-breaking, multi-million dollar settlements.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

Groom Law Group adds top talent from DOL, HHS, and IRS, deepening its 'insider's view' on complex benefits and health regulations for clients.

Euromax Resources raised C$1.6M, but with 84% for overhead and only 9% for its stalled gold project, is this a step forward or just staying afloat?

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

After a 600%+ stock surge and an abrupt SEC trading halt, Charming Medical is now facing class action lawsuits alleging a social media manipulation scheme.

Leveraging a fleet of vintage F-104 jets, Starfighters Space raises $40M and goes public, aiming to disrupt the small satellite launch market.

After bombshell allegations and a stock plunge, Rezolve AI faces a major lawsuit investigation, raising critical questions about AI hype and corporate honesty.

From biopharma to webcomics, shareholder lawsuits reveal the perils of misleading investors. A look at four companies facing legal and financial fallout.